These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 7920310

  • 1. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
    Bacigalupo A, van Lint MT, Tedone E, Moro F, Sanna MA, Longren M, Trespi G, Frassoni F, Occhini D, Gualandi F.
    Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310
    [Abstract] [Full Text] [Related]

  • 2. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S, Zikos P, Van Lint MT, Tedone E, Occhini D, Gualandi F, Lamparelli T, Mordini N, Berisso G, Bregante S, Bruno B, Bacigalupo A.
    Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
    [Abstract] [Full Text] [Related]

  • 3. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study.
    Bregante S, Bertilson S, Tedone E, Van Lint MT, Trespi G, Mordini N, Berisso G, Gualandi F, Lamparelli T, Figari O, Benvenuto F, Raiola AM, Bacigalupo A.
    Bone Marrow Transplant; 2000 Jul; 26(1):23-9. PubMed ID: 10918402
    [Abstract] [Full Text] [Related]

  • 4. Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct).
    Bacigalupo A, Bregante S, Tedone E, Isaza A, Van Lint MT, Moro F, Trespi G, Occhini D, Gualandi F, Lamparelli T, Marmont AM.
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():110-4. PubMed ID: 8932810
    [Abstract] [Full Text] [Related]

  • 5. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS.
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [Abstract] [Full Text] [Related]

  • 6. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections.
    Bacigalupo A, Tedone E, Van Lint MT, Trespi G, Lonngren M, Sanna MA, Moro F, Frassoni F, Occhini D, Gualandi F.
    Bone Marrow Transplant; 1994 Jun; 13(6):783-8. PubMed ID: 7920315
    [Abstract] [Full Text] [Related]

  • 7. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
    Przepiorka D, Ippoliti C, Panina A, Goodrich J, Giralt S, van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M.
    Bone Marrow Transplant; 1994 Apr; 13(4):461-4. PubMed ID: 8019472
    [Abstract] [Full Text] [Related]

  • 8. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
    Ippoliti C, Morgan A, Warkentin D, van Besien K, Mehra R, Khouri I, Giralt S, Gajewski J, Champlin R, Andersson B, Przepiorka D.
    Bone Marrow Transplant; 1997 Sep; 20(6):491-5. PubMed ID: 9313883
    [Abstract] [Full Text] [Related]

  • 9. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality.
    Bacigalupo A, Tedone E, Sanna MA, Moro F, Van Lint MT, Grazi G, Balestreri M, Frassoni F, Occhini D, Gualandi F.
    Haematologica; 1992 Sep; 77(6):507-13. PubMed ID: 1337746
    [Abstract] [Full Text] [Related]

  • 10. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A, Lipton J, Welsh S, Moussa G, Messner H, Mazzulli T.
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [Abstract] [Full Text] [Related]

  • 11. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation.
    Bacigalupo A, Bregante S, Tedone E, Isaza A, Van Lint MT, Trespi G, Occhini D, Gualandi F, Lamparelli T, Marmont AM.
    Transplantation; 1996 Aug 15; 62(3):376-80. PubMed ID: 8779686
    [Abstract] [Full Text] [Related]

  • 12. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E, Suter F, Baruzzo S, Perani V, Moioli F, Remuzzi G.
    Clin Transplant; 1996 Dec 15; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [Abstract] [Full Text] [Related]

  • 13. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
    Nicholson VA, Whimbey E, Champlin R, Abi-Said D, Przepiorka D, Tarrand J, Chan K, Bodey GP, Goodrich JM.
    Bone Marrow Transplant; 1997 Jan 15; 19(1):37-41. PubMed ID: 9012929
    [Abstract] [Full Text] [Related]

  • 14. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, Weisdorf DJ.
    Bone Marrow Transplant; 2002 Dec 15; 30(12):945-51. PubMed ID: 12476289
    [Abstract] [Full Text] [Related]

  • 15. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors.
    Shimokawa T, Morishima Y, Kitaori K, Kato C, Sao H.
    Int J Hematol; 1999 Aug 15; 70(2):119-26. PubMed ID: 10497851
    [Abstract] [Full Text] [Related]

  • 16. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C, Culbert S, Gardner M, Whimbey E, Tarrand J, Chan KW.
    Bone Marrow Transplant; 1996 Apr 15; 17(4):589-93. PubMed ID: 8722360
    [Abstract] [Full Text] [Related]

  • 17. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T, Okamoto S, Matsuoka S, Yajima T, Wakui M, Watanabe R, Ishida A, Iwao Y, Mukai M, Hibi T, Ikeda Y.
    Bone Marrow Transplant; 2000 Apr 15; 25(7):765-9. PubMed ID: 10745263
    [Abstract] [Full Text] [Related]

  • 18. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
    Zaia JA, Schmidt GM, Chao NJ, Rizk NW, Nademanee AP, Niland JC, Horak DA, Lee J, Gallez-Hawkins G, Kusnierz-Glaz CR.
    Biol Blood Marrow Transplant; 1995 Dec 15; 1(2):88-93. PubMed ID: 9118297
    [Abstract] [Full Text] [Related]

  • 19. [Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor].
    Fujisaki T, Gondo H, Uchida N, Matsuo I, Takenaka K, Tanimoto K, Otsuka T, Minematsu T, Minamishima Y, Niho Y.
    Rinsho Ketsueki; 1997 Feb 15; 38(2):142-5. PubMed ID: 9059069
    [Abstract] [Full Text] [Related]

  • 20. Successful treatment of severe cytomegalovirus retinitis with foscarnet and intraocular injection of ganciclovir in a myelosuppressed unrelated bone marrow transplant patient.
    Okamoto T, Okada M, Mori A, Saheki K, Takatsuka H, Wada H, Tamura A, Fujimori Y, Takemoto Y, Kanamaru A, Kakishita E.
    Bone Marrow Transplant; 1997 Nov 15; 20(9):801-3. PubMed ID: 9384487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.